Skip to main content

Acclerys Stock Climbs 6 Percent After Analyst Begins Coverage, Lauds Firm s Clean Balance Sheet

NEW YORK, March 14 (GenomeWeb News) - Shares in Accelrys were up 6 percent, or $.30, at $5.30 in mid-afternoon trading after a securities analyst began covering the company today and gave the stock a 'Buy' rating.


"We believe Accelrys is a sound nanotechnology play," Braswell said in a statement today. "With $59.1 million in gross cash and no long-term debt, Accelrys has arguably the cleanest balance sheet among our coverage universe of companies in the nanotech space.


"The company also has a large, stable base of blue chip customers in the pharmaceutical and materials industries," Braswell added.


J. Andrew Braswell, an analyst with Newbridge Securities, said he expects the stock to reach $9 in 12 months. He said that shares in Accelrys are "currently undervalued, in our opinion."

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.